Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USP Tightens Supply Chain Controls with Risk-Based Vendor Qualification; Aims To Prevent New Heparin Crisis

This article was originally published in PharmAsia News

Executive Summary

The U.S. Pharmacopeia is taking a forward-looking, risk-based approach to protecting the supply chain for biological drug products from intentional and unintentional adulteration, even as it adds testing requirements aimed at preventing a new heparin crisis

You may also be interested in...



U.S. Pharmacopeial Convention Signs Pact With Chinese Regulators To Strengthen Cooperation

BEIJING - In the latest advance in a two-year drive to step up cooperation with Chinese scientists and regulators - during a series of drug and food adulteration scandals that have claimed casualties across the Pacific - the U.S. Pharmacopeial Convention has signed a new agreement with China's Center for Disease Control and Prevention

U.S. Pharmacopeial Convention Signs Pact With Chinese Regulators To Strengthen Cooperation

BEIJING - In the latest advance in a two-year drive to step up cooperation with Chinese scientists and regulators - during a series of drug and food adulteration scandals that have claimed casualties across the Pacific - the U.S. Pharmacopeial Convention has signed a new agreement with China's Center for Disease Control and Prevention

Pharmatech Associates Bikash Chatterjee And Chat Kwan On China's Shift To A Global Standard With New GMP Guidelines: An Interview With PharmAsia News

Headquartered in the San Francisco Bay Area, Pharmatech Associates provides business consulting services in the pharmaceutical, biotech and medical device manufacturing sectors. The company recently held two training programs on the new Chinese Good Manufacturing Practice guidelines in Shanghai. During its Dec. 11 training program, Bikash Chatterjee, the company's president and Chat Kwan, Pharmatech's China president, sat down with PharmAsia News' Shanghai bureau to talk about how the new Chinese GMP guidelines will affect the industry in China and abroad.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC070700

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel